Jens Juul Holst

This is thought to contribute very much to the problems, the complications. So that is in the heart, that is in the liver, that is in the kidneys, that is in the lungs, and that is in the central nervous system.

One of the theories, and it's actually more than a theory these days because it's quite evident, is that one of the ways GLP-1s improve all these conditions, because they do, is by interfering with the inflammation. Reducing the inflammation that causes these problems in the various organs. It's not even miraculous any longer. It's a fact. There is a mechanism behind this.

It also turns out to be true. Because what happens when you're in therapy is that you inhibit your appetite. And because of that, you eat less and then eventually will lose some weight. But if you regain your appetite, then you will start eating again and you will increase in body weight. So if you stop the therapy, of course your body weight will return. But fortunately, there is something you can do. Engage in a change of lifestyle.

Ja se pitäisi olemaan kaksi osaa. Yksi on muuttaminen diettiin. Ja hyvintä on, että voit tehdä tätä. Koska nyt, ensimmäistä kertaa, ehkä pitkällä aikavälillä, olet saanut uudelleen voimasi täällä. Joten se on yksi tärkeä asia. Toinen asia on, että sinun täytyy harjoitella. Sinun täytyy vahvistaa fyysisiä aktiivisuuden tasoja.

Ja kun menet vauhtia, voit tehdä sitä. Voit itse asiassa harjoittaa hieman kasvua yksityiskohtaisesti. Ja se on erittäin tärkeää, koska silloin voit pysyä muskulla. Ja me olemme nähneet, että jos voit pysyä niiden hyvien uusien haasteisiin, niin et tarvitse medikaatiota loppuun, joskus vuoden tai kaksi vuotta.

Kyllä, ja mielestäni se on ehkä hieman riskiä asiaa, koska sinun tarvitset terveydenhoitoa. Toisaalta olet olemassa tilanteessa, jossa olet loppunut liikkuvasti ja tulet ulos vähemmän henkilökohtaisena henkilökohtaisena henkilökohtaisena kuin olit. Ja se ei ole hyvä. Tämä on oikeastaan suosituksena, joka on tärkeä. Kuten periaattorikirjojen jälkeen, jossa on samanlainen henkilökohtainen henkilökohtainen henkilökohtainen henkilökohtainen henkilökohtainen henkilökohtainen henkilökohtainen henkilökohtainen henkilökohtainen

I cannot help to say that I think that there are some societal obligations, again, that should be considered at some stage. But fortunately, there are other things happening. So the first deal we want to be approved of this has gone off patent, and there is now a biosimilar available.

Joten voit ostaa sitä ja se on hankalampi. Se on päivittäinen injektio, joten se ei ole suurin osa. Mutta se toimii, eikä välttämättä ole haastavaa, koska on monia, monia, monia, monia, monia, monia, monia, monia, monia, monia, monia, monia.

There's another development that is really interesting. It's also possible to make GLP-1 agonists that are small molecules, as we call them, small chemical entities, and they're much easier to produce and much cheaper to produce. They haven't really been approved yet, but we will have these. I don't doubt that we will have these small molecules now coming up, and they will be cheaper, and they will put the prices further down. But I must say, in the meantime...

I think that the societies will need to think about how this should be dealt with. And some support, some reimbursement for health reasons, I think would be reasonable. That's what I think. I guess that's something you'd have had a pretty strong opinion about back in your socialist student days. How do you think the young Jens would have felt about all this?

As a young person I marched around on the streets of Copenhagen with a sign saying, research for the people, not for the profit, research for the people, not for the profit. That kind of thinking. So it was much more fun to make something, to make good progress, to get some development going than to...

Just, you know, lock yourself up and try to collect money. And I still feel that way, I must say. But I mean, it is one quarter of the adult population in our societies that will benefit from these therapies and at least one quarter. And we have to find out how to do this.

And do you think governments are listening sufficiently to the scientists? So they were not listening, but now they will be listening, I think. Things have to go hand in hand. You have to be able to provide sufficient medication to a reasonable price, but then I think you can engage the society, because they will win. They will reduce the morbidities. They will avoid some of the sick leaves. They will get the benefit eventually. Well, let's hope so. Jens Juul Hals, thank you very much for sharing your life scientific. Thank you very much.